Keywords: zetia, boosts, response, statin, therapy, merck, co
Zetia boosts response to statin therapy
Article | 25 March 2002
Merck & Co and Schering-Plough's investigational cholesterol absorptioninhibitor, Zetia (ezetimibe), can provide additional reductions in low-density lipoprotein cholesterol levels when used ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
